• Skip to main content
  • Skip to footer
UK Plans to phase out animal testing UK Plans to phase out animal testing
  • About us
  • News
  • Events
  • Careers
cn-bio-organ-on-a-chip-logo
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Resources
  • Technology
  • Products
    • PhysioMimix® Core Microphysiological System
    • Consumables
      • PhysioMimix® Multi-chip plates
      • 3D validated cells
    • Organ-on-a-chip models
    • Gut/Liver-on-a-chip
    • Lung-on-a-chip
    • Support packages
  • Company
    • About us
    • Events
    • News
    • Careers in Biotech
  • Contact us

Discover the applications


Investigate the validated core application areas that our PhysioMimix® products and services support

Learn more

Disease modeling

Metabolic dysfunction-associated steatohepatitis
Hepatitis B
Pulmonary infection
Learn more

Safety toxicology

Drug-induced liver injury
Immune-mediated liver injury
Learn more

ADME

Drug absorption
Drug metabolism
Drug bioavailability
Oligonucleotide delivery
Learn more

Studies as a service


Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

Learn more
icon-nash-1-150x150.png MASLD/MASH
icon-dili-tox-150x150.png Drug-induced liver injury
icon-adme-150x150.png ADME

Explore our solutions


PhysioMimix® is a suite of hardware, consumables and assay protocols that enable you to recreate complex human biology and accurately predict human drug responses.

PhysioMimix Core

cnb1476_physiomimix-core_mark_mocks_system_v2
Learn more

Consumables

Multi-chip plates
3D validated cells
Learn more

Models

Single-organ models
- Liver-on-a-chip model
- Lung-on-a-chip model
Multi-organ models
- Gut/Liver-on-a-chip models

Support packages

PhysioMimix® support packages

Transform drug discovery with predictive human organ models


We are an Organ-on-a-chip company that enables you to generate human-specific efficacy, ADME and safety data with pioneering PhysioMimix® solutions

cnb icons collaborate | organ-on-a-chip company

News

CN Bio Joins NAMs-DC Coalition to Advance Drug Development

Learn more

Areas to explore


New approach methodologies (NAMs), including Organ-on-a-chip (OOC), represent the key to faster, more accurate drug discovery. Explore how to harness the power of PhysioMimix® Core in your lab, or via our contract research services.

Applications icon

Applications

Explore our highly characterized and validated PhysioMimix® Core applications

PhysioMimix application areas

Services icon

Services

Access the power of PhysioMimix® through our contract research service

Our OOC services

icon products 300x300 1 | organ-on-a-chip company

Products

Learn more about PhysioMimix® Core and why it’s helping drive OOC adoption

Explore PhysioMimix Core

Products icon

Technology

Discover why the technology that powers PhysioMimix is like no other

Explore PhysioMimix tech

What’s new?

Article

cnb1622 eurolab article resources tmb v1 | organ-on-a-chip company

Eurolab Magazine article

A Guide to Choosing the Right In Vitro Liver Models for Drug Development Tasks

Industry news

3D cells blog

ISTAND-accepted 3RsC/FDA project

CN Bio participating in ISTAND-accepted 3Rs Collaborative-led project with FDA to build confidence in Liver MPS for DILI…

Partnerships

Inipharm | organ-on-a-chip company

PhysioMimix data for Inipharm

PhysioMimix® Organ-on-a-Chip data supports Inipharm’s INI-822 for metabolic liver disease treatment…

Article

Human-relevant ADMET article

Bridging the ADMET Translational Gap

How New Approach Methodologies and Organ-on-a-Chip Technology Are Redefining Drug Development

Case study

Fluidic organ-on-a-chip toxicology Case study

Fluidic organ-on-a-chip toxicology

There comes a point when static 3D models are no longer sufficient to reflect the complexity of human biology.

As research questions evolve towards systemic effects, multi‑organ interactions, and regulator‑relevant outputs – more advanced fluidic models are needed to deliver unique insight.

Read the case story

Poster

cnb1616 recapitulating immune driven | organ-on-a-chip company

Recapitulating Immune-Driven Hepatotoxicity Using a Liver Microphysiological Platform

Justina Then, Isavella Georgiades, Emily Richardson, Tomasz Kostrzewski – CN Bio

View poster

PhysioMimix® Core: Mimics human physiology like no other


PhysioMimix Core models human-specific biology, which animals lack. Unlock effects that manifest only in human tissue to improve the accuracy and efficiency of drug discovery

  • Human-relevant, translatable data
  • Single-, multi-organ and higher throughput capabilities
  • Flexible and customizable
  • Easy to adopt, simple to use
  • Broad drug modality compatibility, including monoclonal antibodies, oligonucleotides and traditional small molecules
Image of the PhysioMimix Core System

10+

years of OOC industry experience and know-how

70%

of our employees are scientists and engineers

16/20

top pharmaceutical companies use PhysioMimix®

Using the PhysioMimix® System is really straightforward; with a little practice, any tissue culture scientist can master the skills needed for Organ-on-a-chip (OOC) assays

Dr. Déborah Lenart

Research Scientist, Charles River Laboratories

Explore PhysioMimix

Speak to our experts

Request a meeting with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

UK: +44 (0) 1223 737 941

US: +1 415 523 4005

Privacy | Cookies | Regulatory | Accessibility
Website terms | Terms of sale

Product Recycling

©2025 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. GB978184563

Latest news

  • CN Bio Participating in a New Critical Path Institute Coalition of New Approach Methodologies Developers (NAMs-DC) to Support Advancement in Drug Development May 20, 2026
  • Do MHRA and FDA guidelines on non-animal methods in drug development align? March 27, 2026
  • CN Bio to participate in 3Rs Collaborative-led project with FDA to build confidence in Liver MPS for DILI – now ISTAND accepted! January 25, 2026
Cyber Essentials Logo

Modal Title